[1]李宁,柴华,杨志,等.唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效[J].国际放射医学核医学杂志,2017,41(4):247-251.[doi:10.3760/cma.j.issn.1673-4114.2017.04.003]
 Li Ning,Chai Hua,Yang Zhi,et al.Clinical observation of zoledronic acid combined with 89Sr in the treatment of prostate cancer patients with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):247-251.[doi:10.3760/cma.j.issn.1673-4114.2017.04.003]
点击复制

唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第4期
页码:
247-251
栏目:
论著
出版日期:
2017-07-25

文章信息/Info

Title:
Clinical observation of zoledronic acid combined with 89Sr in the treatment of prostate cancer patients with bone metastases
作者:
李宁 柴华 杨志 姚忠强 杨鸿宇 廖光星 肖国有 李党生
530021, 南宁, 广西医科大学附属肿瘤医院核医学科
Author(s):
Li Ning Chai Hua Yang Zhi Yang Hongyu Liao Guangxing Yao Zhongqiang Xiao Guoyou Li Dangsheng
Department of Nuclear Medicine, the Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China
关键词:
前列腺肿瘤锶放射性同位素治疗效果骨转移唑来膦酸
Keywords:
Prostatic neoplasmsStrontium radioisotopesTreatment outcomeBone metastasesZoledronic acid
DOI:
10.3760/cma.j.issn.1673-4114.2017.04.003
摘要:
目的 评估唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效。方法 74例前列腺癌骨转移患者按简单随机分组方法分为3组:唑来膦酸联合89Sr治疗组(A组)25例,年龄46~87岁,中位年龄66岁;单独给予唑来膦酸治疗组(B组)25例,年龄43~89岁,中位年龄65岁;单独给予89Sr治疗组(C组)24例,年龄47~85岁,中位年龄66岁。其中,B组和C组为对照组。随访6个月,观察患者骨骼疼痛缓解情况和骨转移病灶数目改善情况。结果 3组患者的基线特征相似。治疗后,A组总的疼痛缓解率为88.0%,B组和C组分别为72.0%和79.2%,A组疼痛缓解情况与B组和C组相比差异有统计学意义( χ2=8.959,P<0.05)。A组骨转移病灶好转率为88.0%,B组和C组分别为44.0%和75.0%,A组病灶好转情况分别与B组、C组相比,差异有统计学意义(χ2=9.096,P<0.05)。结论 唑来膦酸联合89Sr治疗前列腺癌骨转移较单独给药具有更好的缓解疼痛作用,89Sr治疗可有效减少骨转移病灶,提高患者的生活质量。
Abstract:
Objective To evaluate the clinical curative effect of zoledronic acid combined with 89Sr for the treatment of prostate cancer patients with bone metastases.Methods A total of 74 prostate cancer patients were randomly divided into three groups according to treatment,as follows:Group A (n=25;median age,66 years;age range,46-87 years),zoledronic acid with 89Sr;Group B (n=25;median age,65 years;age range,43-89 years),zoledronic acid;and Group C (n=24;median age,66 years;age range,47-85 years),89Sr.Groups B and C were the control groups.All patients were followed up for 6 months,during which the status of bone pain relief and improvement in the number of bone metastatic lesions were observed.Results The three groups showed similar baseline characteristics.Total pain relief efficiency in group A was 88.0%,while those of the control groups were 72.0%(group B) and 79.2%(group C).Pain palliation of group A significantly differed from those of groups B and C (χ2=8.959,P<0.05).Regression of bone metastatic lesions in group A was 88.0%,while those of the control groups were 44.0%(group B) and 75.0%(group C).Significant difference was found between group A and the two control groups (χ2=9.096,P<0.05).Conclusion Combined therapy of zoledronic acid and 89Sr in prostate cancer patients with painful bone metastases was more effective in treating pain and improving the quality of life than separate administration of zoledronic acid or 89Sr.

参考文献/References:

[1] 王卫星. 89SrCl2联合唑来膦酸治疗前列腺癌骨转移[J]. 四川医学, 2012, 33(12):2158-2159. DOI:10.3969/j.issn.1004-0501.2012. 12.055. Wang WX. Combined therapy of 89Sr-chloride and zoledronic acid in prostate cancer patients with bone metastases[J]. Sichuan Med J,2012, 33(12):2158-2159.
[2] Carlin BI, Andriole GL. The natural history, skeletal complications,and management of bone metastases in patients with prostate carcinoma[J]. Cancer, 2000, 88(12 Suppl):S2989-2994. DOI:10.1002/1097-0142(20000615)88:12+<2989:AID-CNCR14>3.0.CO;2-Q.
[3] Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity[J]. J Cell Biol, 2004, 91(4):718-729. DOI:10.1002/jcb.10662.
[4] Clark JC, Dass CR, Choong PF. Current and future treatments of bone metastases[J]. Expert Opin Emerg Drugs, 2008, 13(4):609-627. DOI:10.1517/14728210802584217.
[5] Facchini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events(SRE)[J]. J Exp Clin Cancer Res, 2007, 26(3):307-312.
[6] Fitch M, Maxwell C, Ryan C, et al. Bone metastases from advanced cancers:clinical implications and treatment options[J]. Clin J Oncol Nurs, 2009, 13(6):701-710. DOI:10.1188/09.CJON.701-710.
[7] 石远凯. 肺癌诊断治疗学[M]. 北京:人民卫生出版社, 2008:381-382. Shi YK. Diagnosis and treatment of lung cancer[M]. Beijing:People’s Medical Press, 2008:381-382.
[8] Storto G, Klain M, Paone G, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases[J]. Bone,2006, 39(1):35-41. DOI:10.1016/j.bone.2005.12.004.
[9] Kamba T, Kamoto T, Maruo S, et al. A phase Ⅲ multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease:results of the ZAPCA trial[J/OL]. Int J Clin Oncol, 2017, 22(1):166-173[2016-12-16]. https://link.springer.com/article/10.1007%2Fs10147-016-1037-2. DOI:10.1007/s10147-016-1037-2.
[10] Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan[J]. Cancer, 1988, 61(1):195-202. DOI:10.1002/1097-0142(19880101)61:1<195:AID-CNCR2820610133>3.0.CO;2-Y.
[11] Kotake T, Usami M, Akaza H, et al. Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer:a multicenter, randomized, controlled trial in Japan[J]. Jpn J Clin Oncol, 1999, 29(11):562-570. DOI:10. 1093/jjco/29.11.562.
[12] Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer[J]. N Engl J Med, 1998, 339(15):1036-1042. DOI:10.1056/NEJM199810083391504.
[13] Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam:a double-blind placebo-controlled clinical trial[J]. J Clin Oncol, 1998, 16(4):1574-1581. DOI:10.1200/JCO. 1998.16.4.1574.
[14] 白永利, 王林, 董莉. 唑来膦酸钠联合89SrCl2治疗骨转移瘤的临床疗效[J]. 现代肿瘤医学, 2016, 24(5):815-818. DOI:10.3969/j.issn.1672-4992. 2016.05.039. Bai YL, Wang L, Dong L. Clinical observation of zoledronic acid combined with 89SrCl2 in the treatment of bone metastasis tumor[J]. Modern Oncol, 2016, 24(5):815-818.
[15] Body JJ. Bone metastases and tumor-induced hypercalcemia[J]. Curr Opin Oncol, 1992, 4(4):624-631. DOI:10.1097/00001622-199208000-00005.
[16] Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer[J]. Semin Oncol, 2002, 29(3 Suppl 11):S134-144. DOI:10.1016/S0093-7754(02)70137-1.
[17] 蒙荣钦, 李昌林, 朱云芝, 等. 唑来膦酸联合89Sr治疗恶性肿瘤晚期多发骨转移疗效观察[J]. 中华实用诊断与治疗杂志, 2013, 27(3):277-278. Meng RQ, Li CL, Zhu YZ, at al. Clinical observation of zoledronic acid combined with 89SrCl2 in the treatment of multiple bone metastases tumor[J]. J Chin Pract Diagn Ther, 2013, 27(3):277-278.
[18] Yamada K, Yoshimura M, Kaise H, et al. Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases[J]. Exp Ther Med, 2012, 3(2):226-230. DOI:10.3892/etm.2011.405.

相似文献/References:

[1]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
 Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[2]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
 Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[3]刘辰,杨悦,张雪宁,等.MRI和1997年版Partin表对前列腺癌病理特征预测准确性的对比研究[J].国际放射医学核医学杂志,2015,39(2):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
 Liu Chen,Yang Yue,Zhang Xuening,et al.Accuracy of MRI and 1997 edition of Partin tables in predicting the pathological features of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
[4]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
 Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[5]张晖,段清,卓娜,等.经直肠超声引导下“6+X”点法前列腺穿刺活检诊断前列腺癌的临床价值分析[J].国际放射医学核医学杂志,2015,39(4):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
 Zhang Hui,Duan Qing,Zhuo Na,et al.Meta-analysis of the diagnostic value of transrectal ultrasound-guided “6+X” points biopsy in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
[6]郑玉明,程霞,郑棒.自制90Sr保持架在皮肤病敷贴治疗中的辐射防护作用[J].国际放射医学核医学杂志,2014,38(1):19.[doi:10.3760/cma.j.issn 1673-4114.2014.01.005]
 Zheng Yuming,Cheng Xia,Zheng Bang.Effects of serf-made 90Sr applicator retainer on radiation protection in treatment of skin disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):19.[doi:10.3760/cma.j.issn 1673-4114.2014.01.005]
[7]张龙敏,刘爱连.前列腺癌MRI诊断技术研究进展[J].国际放射医学核医学杂志,2014,38(1):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
 Zhang Longmin,Liu Ailian.Advances in MRI diagnosis of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
[8]刘辰,杨悦,张雪宁,等.CT/MRI图像融合在前列腺癌IMRT中的应用进展[J].国际放射医学核医学杂志,2014,38(4):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
 Liu Chen,Yang Yue,Zhang Xuening,et al.CT/MRI image fusion in intensity modulated radiation therapy for prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
[9]韦赐秋.中老年男性血清前列腺特异性抗原测定的临床价值[J].国际放射医学核医学杂志,2010,34(5):302.[doi:10.3760/cma.j.issn.1673-4114.2010.05.014]
[10]徐慧琴,薛杨央,赵学峰,等.18F-FDG PET-CT诊断前列腺癌复发与转移的价值[J].国际放射医学核医学杂志,2011,35(2):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
 XU Hui-qin,XUE Yang-yang,ZHAO Xue-feng,et al.Value of 18F-FDG PET-CT in diagnoss of prostate cancer recurrence and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
[11]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
 YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]

备注/Memo

备注/Memo:
收稿日期:2016-12-16。
基金项目:广西医疗卫生适宜技术开发与推广应用项目(S201633);广西教育厅2016年中青年教师基础能力提升项目(KY2016LX025);2014广西医科大学青年基金课题(GXMUYSF201408)
通讯作者:李党生,Email:LDS101@126.com
更新日期/Last Update: 2017-07-31